Akili, a trailblazer in therapeutic prescription digital medicine has closed successfully it’s $55 million financing Series C events of medicine. This funding follows a plentiful events, including investigate, developing and psychoanalysis a novel digital medicine named AKL- T01. This flagship product of Akili aimed to treat a type of cognitive disease- attention deficit/hyperactivity chaos (ADHD).… Continue reading Digital Medicine Platform for Treatment of Cognitive Disorder